Proposal to list medical devices supplied by Hologic (Australia & New Zealand) Pty Limited - EXTENDED TO 14 JUNE 2022
Pharmac is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule.
What we’re proposing
Pharmac is seeking feedback on a proposal to list medical devices supplied by Hologic (Australia & New Zealand) Pty Limited (“Hologic”) in Part III of Section H of the Pharmaceutical Schedule from 1 August 2022 in the following categories:
- Laboratory equipment and consumables; and
- Medical imaging, software and associated products (“medical imaging”).
Consultation closes at 4pm Tuesday 14 June 2022 and feedback can be emailed to nerissa.ramlall@pharmac.govt.nz.
What would the effect be?
From 1 August 2022 medical devices supplied by Hologic in the categories noted above would be listed under a proposed national agreement for all DHB hospitals to purchase under, subject to consultation and approval by Pharmac’s board or delegate (“Agreement”).
The Agreement would not be for sole supply and DHBs can continue to purchase other suppliers’ brands of laboratory equipment and consumables and medical imaging, software and associated products.
The Agreement would supersede any existing DHB agreements with Hologic for the medical devices included in the Agreement. Any medical device listed in the Agreement and purchased by a DHB would be in accordance with the terms and conditions, including price, stated in the Agreement effective from the date of listing in the Pharmaceutical Schedule.
Pricing for the medical devices in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by Pharmac.
Who we think will be interested
- DHB clinical staff in a range of different clinical settings including but not limited to:
- Clinicians
- Laboratory managers, scientists, technicians and other laboratory staff
- Radiology
- Nurses
- Clinical engineers and maintenance services
- Procurement and supply chain personnel
- Suppliers and wholesalers
About the medical devices
Laboratory equipment
Laboratory equipment and consumables are used in the collection, receipt, preparation and analysis of human biological material for the purpose of supporting patient diagnosis, management and treatment.
Medical imaging
Medical imaging is the technique and process of imaging the interior of a body for clinical analysis and medical intervention, as well as visual representation of the function of some organs or tissues.
Why we’re proposing this
Pharmac has previously released the following Requests for Proposals (RFPs):
- supply of laboratory equipment and consumables
- supply of medical imaging equipment, associated consumables, accessories, software and services and maintenance(external link)
The RFPs were for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
Pharmac has been working with suppliers who responded to the RFPs to seek provisional agreements. This proposal is the latest to arise from these processes and we expect to consult on further provisional agreements with suppliers in these categories throughout 2022.
Details about our proposal
Pharmac has entered into a provisional agreement with Hologic for the supply of laboratory equipment and medical imaging products.
The proposal would result in Pharmaceutical Schedule listings for:
|
Category |
Brands |
Line items |
|---|---|---|
|
Laboratory equipment |
Aptima, Biorear, Cytobrush, Cytolyt, Hologic, Panther, Panther Fusion, PresevCyt, Procleix, Rapid FFN, ThinPrep, Tomcat, Urocyt, Wallach |
217 |
|
Medical imaging |
ATEC, Celero, Eviva, Fluoroscan, Hologic, Horizon, Mammopad Selenia Dimensions, SSI Imaging |
95 |
Further information, including pricing and contractual details, has been provided to DHB Procurement personnel. Clinicians interested in further detail on what this change means for their DHB should engage with their Procurement teams.
To provide feedback
Send us an email: nerissa.ramlall@pharmac.govt.nz by 4pm 14 June 2022.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.
We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.